Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized
The Texas Department on Aging has officially launching a "Texas Cares" website -- http://www.txcares.org -- to help older Texans and people with disabilities get information that may help them obtain thei
Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials. The drug could potentially save the l
Following a recent judgment of the European Court of Justice in the 'Novartis' case (Case 106/01), the MHRA has decided to change its policy concerning the assessment of generic equivalents of line extension product
ACE inhibitors, a type of medication often used to treat high blood pressure or heart disease, can lower mortality rates for people who have diabetes -- whether they have cardiovascular disease or not, according to a study published in the June issue of
Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon? (albumin-interferon alpha) in patients with chronic hepatitis C who are na? to interferon-alpha
The weight loss medication Xenical? (orlistat) has been shown to be significantly more effective than lifestyle changes alone in managing weight in overweight adolescents, according to new study results presented today at E
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded two contracts to support the production and clinical testing of an invest
Bionomics Limited and Southern Cross University announced today that they had established a collaboration to discover new drugs targeting epileps
Amgen Inc., the world's largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene e
People who have diabetes are far more likely to die from coronary artery disease than people who don't have diabetes. In fact, it is the leading cause of death for people with type 2 diabetes. Contributing to this problem is the fact that treatments that are effective for people who don't have diabetes often are not as effective for those who do.
One such treatment is percutaneous coronary intervention (PCI), a group of procedures (such as balloon angioplasty) for opening narrowed arteries. Stents, which are used to prop open blocked coronary vessels, have proved to be an important complement to PCI. But in people with diabetes, major arteries often become reclogged after PCI, despite the use of stents. This problem is called restenosis, which can be treated with a second PCI procedure.
The rate of restenosis following PCI for people who don't have diabetes is 20-40 percent after six months. For people who do have diabetes, it is 32-66 percent.
But now researchers in Korea, under a grant provided by the Basic Research Program of the Korea Science & Engineering Foundation, have found that people with diabetes who take the drug rosiglitazone following coronary stent implantation are substantially less likely to require a second PCI procedure due to restenosis. The drug, which sells under the brand name Avandia, reduced restenosis rates by 54 percent in people who have type 2 diabetes. Those who experienced the reduced restenosis rates took 8 mg of the drug prior to catheterization and 4 mg daily thereafter. Researchers believe the reduced restenosis rate may occur partly because the drug lowers inflammation, which can lead to clogging of the arteries.
Rosiglitazone is commonly prescribed for people who have diabetes as a once- or twice-daily medication that helps the body more effectively use its own natural insulin to control blood sugar levels. It is part of a class of drugs known as thiazolidinediones (TZDs). A separate study, published last year in the American Heart Journal, found that another TZD, pioglitazone, may also aid in reducing restenosis.
http://www.diabetes.org/